Four Children with Multidrug-resistant Acinetobactor baumanii Infections in the Intensive Care Units of a University Hospital

단일 3차 의료기관 집중치료실에서 발생한 다약제내성 Acinetobacter baumannii의 4례

  • Lee, Kyung Suk (Department of Pediatrics, College of Medicine, Kyung Hee University) ;
  • Lee, Gyu Min (Department of Pediatrics, College of Medicine, Kyung Hee University) ;
  • Yoon, Hoi Soo (Department of Pediatrics, College of Medicine, Kyung Hee University) ;
  • Chung, Sa Jun (Department of Pediatrics, College of Medicine, Kyung Hee University) ;
  • Cha, Sung-Ho (Department of Pediatrics, College of Medicine, Kyung Hee University) ;
  • Chun, Hee-Kyung (Department of Infection Control, College of Medicine, Kyung Hee University)
  • 이경석 (경희대학교 의과대학 소아과학교실) ;
  • 이규민 (경희대학교 의과대학 소아과학교실) ;
  • 윤회수 (경희대학교 의과대학 소아과학교실) ;
  • 정사준 (경희대학교 의과대학 소아과학교실) ;
  • 차성호 (경희대학교 의과대학 소아과학교실) ;
  • 천희경 (경희대학교병원 감염관리실)
  • Received : 2011.04.25
  • Accepted : 2011.06.06
  • Published : 2011.06.25

Abstract

The Multidrug-resistant Acinetobactor baumanii (MDRAB) is an opportunistic pathogen. Patients with long periods of hospital stay and/or under intensive care unit (ICU) receiving invasive management are more susceptible to this pathogen. In this report, four children with MDRAB infection are reviewed and described their clinical characteristics. There had been concurrent outbreaks of MDRAB infection in adult patients in the ICU at this period of time. The first child had received a craniotomy and epidural hematoma evacuation. The second child was admitted for status epilepticus with hydrocephalus. The third child had pneumonia with status epilepticus with hydrocephalus. The fourth child had poor activity due to hypoxic ischemic encephalopathy and convulsive disorder. Except the fourth child, all had not been exposed to carbapenem prior to infection of MDRAB. That imply the cause of MDRAB infections may be associated with invasive management and prolonged hospitalization together with the previous exposure to carbapenem in our cases. We would like to emphasize the importance and minimizing the spread of hospital infection in patients under prolonged intensive care management regardless of the use of carbapenem.

Acinetobactor baumanii 는 기회 감염균으로 carbapenem의 사용이 증가하면서 MDRAB와 같은 내성균으로 출현하고 있다. 저자들은 경희의료원에서 carbapenem을 투약받지 않았더라도 집중치료실에 장기간 입원하여 기관삽관과 인공호흡기 치료를 받거나 침습적인 수술을 받아 도관을 유지하는 환아에서 MDRAB가 동정되었다는 것을 확인하였다. carbapenem을 사용하지 않았더라도 장기간 집중치료실에 입원할 것으로 예상되는 환자들에게 원내전파를 통한 감염을 최소화하기 위하여 원내감염관리에 최선을 다해야 할 것이기에 이상의 증례를 통하여 보고한다.

Keywords

References

  1. Fulnecky EJ, Wright D, Scheld M, Kanawati L, Shoham S. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect 2005;51:e249-51. https://doi.org/10.1016/j.jinf.2005.04.003
  2. Chang PY, Hsueh PR, Wu PS, Chan PC, Yang TT, Lu CY, et al. Multidrug-resistant Acinetobacter baumannii isolates in pediatric patients of a university hospital in Taiwan. J Microbiol Immunol Infect 2007;40:406-10.
  3. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-buisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic methods. J Clin Microbiol 1994;32:2677-81.
  4. Moon SM, Son JS, Lee HJ, Chun HK, Kim ML, Lee MS. The analysis of risk factor and infection control of carbapenem-resistant Acinetobacter baumannii in a medical intensive care unit. Korean J Nosocomial Infect Control 2009;14:72-8.
  5. Yang HY, Lee HJ, Suh JT, Lee KM. Outbreaks of imipenem resistant Acinetobacter baumannii producing OXA-23 beta-lactamase in a tertiary care hospital in Korea. Yonsei Med J 2009;50:764-70. https://doi.org/10.3349/ymj.2009.50.6.764
  6. Lopez-Hernandez S, Alarcon T, Lopez-Brea M. Carbapenem Resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain. Eur J Clin Microbiol Infect Dis 1998;17:282-5.
  7. Go ES, Urban C, Janice B, Kreiswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polimyxin B and sulbactam. Lancet 1994;344:1329-32. https://doi.org/10.1016/S0140-6736(94)90694-7
  8. Paton R, Miles RS, Hood J, Amyes SGB. ARI-1/betalactamase- mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 1993;2:81-8. https://doi.org/10.1016/0924-8579(93)90045-7
  9. Cisneros JM, Rodriguez-Bano J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002;8:687-93. https://doi.org/10.1046/j.1469-0691.2002.00487.x
  10. Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, et al. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis 2008;62:67-80. https://doi.org/10.1016/j.diagmicrobio.2008.04.012
  11. Patzer JA, Dzierzanowska D, Turner PJ. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007). J Antimicrob Chemother 2008;62:369-75. https://doi.org/10.1093/jac/dkn184
  12. Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin againts multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 1998;41:494-5. https://doi.org/10.1093/jac/41.4.494